|Articles|April 7, 2014

FDA Approves ResolutionMD for Diagnosis on Mobile Devices

Author(s)Liza Haar

Calgary Scientific’s ResolutionMD received FDA clearance for diagnosis on mobile devices for most imaging modalities.

ResolutionMD, an enterprise image-viewing solution, has been approved by the U.S. Food and Drug Administration (FDA) for diagnosis on mobile devices for most imaging modalities.

Calgary Scientific, Inc., the company behind ResolutionMD, worked with multiple radiologists worldwide to clinically validate the solution before submitting it to the FDA. ResolutionMD allows doctors to securely view patient images and reports from a variety of computers and mobile devices. It also offers the ability to collaborate with other practitioners and diagnose from any location.

The mobile medical diagnosis software of ResolutionMD can be integrated into any EMR and plugged into existing distributed storage systems. The FDA’s safety and effectiveness review found ResolutionMD to be substantially equivalent to PACS or dedicated diagnostic workstations.

ResolutionMD has been cleared to diagnose modalities such as CR, DR, radio-fluoroscopy, angiography, ultrasound, nuclear medicine, endoscopy and ophthalmology.


Related to this article

Foundation Model-Based Chest X-Ray AI Software Gets FDA Nod
Reportedly one of the first FDA-cleared chest X-ray AI software platforms derived from a foundation model, the Chest Xray software facilitates detection and localization of lung nodules, pneumothorax, mediastinal abnormalities and other thoracic abnormalities.
Does kV Still Matter in Photon-Counting CT?
Emerging research demonstrates the increasing stability of attenuation on clinically relevant VMIs with photon-counting CT and a redefined role of kV that may have implications for longitudinal quantitative CT.
CT Radiation Dosing: Where Things Stand, Part 2
In the second of a two-part interview, Kalpana Kanal, PhD, and Mahadevappa Mahesh, MS, PhD, FAPPM, FACR, discussed future directions for research on CT radiation dosing, including the potential of indication-specific diagnostic reference levels (DRLs).